Abstract 2270P
Background
Pancreatic Adenocarcinoma (PAAD) is a highly fatal disease and often associated with a poor prognosis. The development of diabetes mellitus (DM) is an important risk factor. There have been studies exploring markers or prognostic models that affect the prognosis of patients with pancreatic cancer, but there are few studies on pancreatic cancer-associated diabetes mellitus (PCDM) patients.
Methods
The differentially expressed genes (DEGs) between DM and non-DM were detected and selected to build model. PCDM patients were randomly divided into training (70%) and test cohort (30%). Then the univariate COX was performed to screen OS associated genes (p < 0.05) in the training cohort. The LASSO-penalized COX regression and ten-fold cross validation were used to train and select models. The risk score was calculated and verified in both training and test cohort. GSVA, ESTIMATEScore, CIBERSORT and ssGSEA were used to compare the tumor microenvironment (TME). Moreover, the value of genes used in the model was detected on single cell level.
Results
Totally 197 patients (including 60 with DM) were enrolled, 23 genes from DEGs were related to the OS of PCDM patients in the training cohort, and 10 genes were selected to construct the risk model. The risk score for each subject was calculated as follow: risk score=0.434*ACACA+0.119*ATG7+0.373*DEFB123+0.135*FSTL3-0.168*NIPSNAP3B-0.069*RASSF1+0.225*RBPJ+0.364*SLC35F2-0.168*SLC37A1-0.145*ZC3H12D. The C-index was 0.83 in the training cohort (hazard ratio [HR] = 7.61, p < 0.001) and 0.76 in the test cohort (HR = 3.22, p = 0.015). According to the median value -0.054, PCDM patients were split into different risk groups, and patients in the low-risk group showed more enriched T cell related pathways (60 vs 1), higher ImmuneScore (p < 0.001), and more CD8 positive T cell infiltration (CIBERSORT: p < 0.001; ssGSEA: p < 0.001). We calculated the score of genes used in the model in single cells. Malignant cells with the highest score (top 10%) had enhanced activities of angiogenesis.
Conclusions
The prognostic model showed potential value in predicting the OS of patients with PCDM. Patients with low-risk score had a hotter TME and might benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2284P - Pre-clinical assessment of the therapeutic potential of a CD80-Fc-armed oncolytic virus (VSV-GP-CD80Fc)
Presenter: Andreas Ackermann
Session: Poster session 08
2285P - Lower response to COVID-19 booster dose vaccination on cancer patients comparing to healthy controls
Presenter: Pedro Cruz
Session: Poster session 08
2286P - COVID-19 vaccinations in cancer patients (pts): An individual participant data meta-analysis of the International Consortium on COVID vaccination in cancer
Presenter: Ha Mo Linh Le
Session: Poster session 08
2288P - Recolony-treating solid tumors with a bacteria-based approach
Presenter: Egle Katkeviciute
Session: Poster session 08
2289P - Determining anti-cancer efficacy of a reversible LSD1 inhibitor, EXS74539, in primary AML tissues with limited thrombocytopenic effects
Presenter: Christophe Boudesco
Session: Poster session 08
2291P - WU-NK-101, best in class memory-NK cell, has key features vital for adoptive cell therapy (ACT) in solid tumors (ST)
Presenter: John Muth
Session: Poster session 08
2292P - Prevalence of druggable EGFR genomic alterations in solid tumours other than lung cancer
Presenter: Tomohiro Kondo
Session: Poster session 08
2293P - Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers
Presenter: Carlotta Catozzi
Session: Poster session 08
2294P - Whole genome sequencing to define the germline-somatic interaction in young-onset lung cancer
Presenter: Jaclyn LoPiccolo
Session: Poster session 08